RVL Pharmaceuticals plc OSMT
Set alert
1.11 0.00 0.00%
At close
1.09 Day range 1.15
52-week range unavailable
- Open
- 1.14
- Prev close
- 1.11
- Mkt cap
- 92.45M
- Vol
- 296.32K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.09
- High
- 1.15
- Forward P/E
- -1.59
- Beta
- 1.96
- Short ratio
- 0.53
- Inst. own
- 35.23%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 15, 2021
- 50-d avg
- 1.15
- 200-d avg
- 2.48
- 1y target
- 5.75
Financial health
Altman Z-Score
-8.04 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
3 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
Valuation
P/E -3.2×
FY 2016 5y median -3.2× FY 2020
P/S 1.5×
FY 2016 5y median 1.5× FY 2020
P/B 2.8×
FY 2016 5y median 0.9× FY 2020
P/FCF 17.9×
FY 2016 5y median 10.5× FY 2020
EV/EBITDA -7.5×
FY 2016 5y median -10.7× FY 2020
EV/Sales 2.0×
FY 2016 5y median 2.3× FY 2020
FCF Yield 5.6%
FY 2016 5y median 8.1% FY 2020
Profitability
Gross Margin 58.1%
FY 2016 5y median 49.1% FY 2020
Operating Margin 1.0%
FY 2016 5y median 1.3% FY 2020
Net Margin -44.7%
FY 2016 5y median -41.5% FY 2020
ROE -84.8%
FY 2016 5y median -28.3% FY 2020
ROIC 0.5%
FY 2016 5y median 0.7% FY 2020
ROA -21.5%
FY 2016 5y median -13.7% FY 2020
Growth (YoY)
Revenue -25.9%
FY 2016 FY 2020
Operating Income -42.8%
FY 2016 FY 2020
EPS (diluted) 75.4%
FY 2016 FY 2020
Free Cash Flow -51.0%
FY 2016 FY 2020
Financial Health
Current Ratio 3.1×
FY 2016 5y median 1.5× FY 2020
Quick Ratio 2.8×
FY 2016 5y median 1.3× FY 2020
Debt / Equity 2.3×
FY 2016 5y median 0.8× FY 2020
Net Debt / EBITDA -2.2×
FY 2016 5y median -3.5× FY 2020
Interest Coverage 0.1×
FY 2016 5y median 0.2× FY 2020
Dividends
Dividend Yield 0.0%
FY 2016 5y median 0.0% FY 2020
Payout Ratio 0.0%
FY 2016 5y median 0.0% FY 2020
Annual · latest fiscal year ends 2020-12-31